If you have been reading about Semax and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Free acid form of the heptapeptide; depends on terminal groups |
| Molecular mass | About 813.9 g/mol | Average mass used for mass spectrometry confirmation |
| Appearance | White to off-white solid | Supplied as a lyophilised powder; hygroscopic |
| Solubility class | Freely soluble in aqueous media | Water, saline, and phosphate buffers; limited organic solubility |
| Typical storage temperature | -20 degrees Celsius | Long term and dry; short working periods may use 2 to 8 degrees Celsius |
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Semax 是人工设计的七肽，序列为 Met-Glu-His-Phe-Pro-Gly-Pro，骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性，同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。
当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
=== Characterisation and family === After his first scenes aired, Kipa-Williams wrote a detailed biography from his character's perspective on social media. He revealed that Ari's full name is Ariki Wiremu Parata, and that he moved to Australia from New Zealand twelve years prior to his debut appearance. He continued: "I've had a few challenges and those challenges brought me to Summer Bay... I love my whanau (family), I'll do anything for them, but never cross me. I didn't know the guy who died but my heart goes out to the family. As for me, I guess you'll find out if I stay in the bay or if I go when Home and Away returns in 2020." The character's profile on TVNZ confirmed that Ari had served time in prison, which he tries to keep to himself. Kipa-Williams revealed that Ari was involved in "a life of crime", but made the decision to change and leave it behind him. However, "he wrestles with his past" and is constantly "frustrated" with the few opportunities available to him because of his criminal record. Ari is "fiercely protective" of the family, especially since his brother's death, and he has become the patriarch of the family. Although this has left him feeling "a little out of his depth". Ari dislikes confrontation and he struggles to express his emotions, but he is keen to change "his path." Kipa-Williams stated "he has made some strong choices but he is a little bit lost.
Plantar fasciitis is usually diagnosed by a healthcare provider based on a history, risk factors, and clinical examination. Palpation along the inner aspect of the heel bone on the sole may elicit tenderness during an examination. The foot may have limited dorsiflexion due to tightness of the calf muscles or the Achilles tendon. Dorsiflexion may elicit pain. Diagnostic imaging is not usually indicated. Occasionally, a physician may decide imaging studies (such as X-rays, diagnostic ultrasound, or MRI) are warranted to rule out other diagnoses. Other possible diagnoses include fractures, tumors, or systemic disease should pain not respond to conservative medical treatments. Bilateral heel pain or heel pain in the context of a systemic illness may indicate further diagnosis. Under these circumstances, tests such as a CBC or serological markers of inflammation, infection, or autoimmune disease such as C-reactive protein, erythrocyte sedimentation rate, anti-nuclear antibodies, rheumatoid factor, HLA-B27, uric acid, or Lyme disease antibodies may be conducted. Neurological deficits may prompt an investigation with electromyography to check for nerve or muscle damage. An incidental finding associated with this condition is a heel spur, a small bony calcification on the calcaneus (heel bone), which can be found in up to 50% of patients. In such cases, the plantar fasciitis produces the heel pain, rather than the spur. The condition creates the spur, though the clinical significance of heel spurs remains unclear.
in vivo 19F MRS can be used to monitor the uptake and metabolism of drugs, study the metabolism of anesthetic, determine cerebral blood flow, and measure, via fluorinated compounds ("probes"), various parameters like pH, oxygen levels, and metal concentration.
Sources: en.wikipedia.org
== History == Cyclofenil was first introduced for medical use in 1970 under the brand name Ondogyne in France. Subsequently, it was introduced throughout the world under a variety of other brand names, including its most well-known brand name Sexovid.
Clostridioides difficile has a highly diverse epigenome, with 17 high-quality methylation motifs reported so far, the majority pertaining to the 6mA type. Methylation at one of these motifs - CAAAAA, was shown to impact sporulation, a key step in C. difficile disease transmission, as well as cell length, biofilm formation, and host colonization. At least eight mainly temperate bacteriophages have been isolated from C. difficile, ranging in genome size from about 30 to about 60 kbp. Both environmentally and clinically derived C. difficile strains carry a diverse and prevalent set of prophages. Canada Pathogen Safety Data Sheets: Infectious Substances – Clostridium difficile, Public Health Agency, Canada, September 10, 2014. Type strain of Clostridium difficile, BacDive—the Bacterial Diversity Metadatabase
Mycofactocin is thought to play a role in redox pathways involving nicotinoproteins, enzymes with non-exchangeable bound nicotinamide adenine dinucleotide (NAD). This notion comes largely from comparative genomics work that highlighted the many parallels between mycofactocin and pyrroloquinoline quinone (PQQ). In both cases, maturation of the RiPP requires post-translational modification of a precursor peptide by a radical SAM enzyme, the system appears in very similar form in large numbers of species, the product appears to be used within the cell rather than exported, and several families of enzymes occur exclusively in bacteria with those systems. The number of putatively mycofactocin-dependent oxidoreductases encoded by a single genome can be quite large: at least 19 for Rhodococcus jostii RHA1, and 26 for the short chain dehydrogenase/reductase (SDR) family alone in Mycobacterium avium. The enzyme LimC (Q9RA05), a nicotinoprotein carveol dehydrogenase (EC 1.1.1.n4), is shown to use both MFT and PMFT in vitro.
Sources: en.wikipedia.org
=== Chalcogenides and pnictides === The known chalcogenides of americium include the sulfide AmS2, selenides AmSe2 and Am3Se4, and tellurides Am2Te3 and AmTe2. The pnictides of americium (243Am) of the AmX type are known for the elements phosphorus, arsenic, antimony and bismuth. They crystallize in the rock-salt lattice.
=== Military lull (August) === Active hostilities slowed in August 2026, when the formal 60-day deadline set by the June MoU officially expired. The Strait of Hormuz remained disrupted during this period and mediators Oman and Qatar were involved in backdoor diplomacy, slowing world energy shipping to a fraction of its pre-war volume.
== Arrival in Spain == In Madrid, Alexander von Humboldt pursued the idea of a scientific expedition to Spanish America, despite the usual restrictions on foreign travel in Spanish colonies. Through the assistance of Don Mariano Luis de Urquijo, Spain’s First Secretary of State, whom Humboldt had previously met in London, he was introduced to King Charles IV of Spain. The king granted Humboldt and his companion, Aimé Bonpland, official permission to travel throughout Spanish America for scientific purposes. The royal passports granted Humboldt and Bonpland extensive rights, including the use of scientific instruments, freedom of movement, and the authority to conduct research throughout Spanish territories. Colonial officials were instructed to assist them as needed. Such privileges were exceptional, given that Spain had historically allowed very few foreign scientific missions in its colonies, due to longstanding policies of restricting access to outsiders for reasons of state security, economic monopoly, and religious protection. The level of trust and freedom granted to Humboldt was unprecedented for a non-Spaniard. Humboldt recognized that Spain’s primary interest in granting permission was related to his expertise in mineralogy and the potential for discovering new mineral resources, rather than purely scientific advancement.
Sources: en.wikipedia.org
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.
It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.
Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.
The sequence is Met-Glu-His-Phe-Pro-Gly-Pro, a seven-residue peptide. The first four residues correspond to the ACTH(4-10) fragment, and Pro-Gly-Pro is added at the C-terminus. N-acetylated versions also appear in the literature and differ in mass.